Axsome Therapeutics (AXSM) Receivables (2022 - 2025)
Historic Receivables for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $215.8 million.
- Axsome Therapeutics' Receivables rose 5596.52% to $215.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.8 million, marking a year-over-year increase of 5596.52%. This contributed to the annual value of $155.5 million for FY2024, which is 4489.84% up from last year.
- According to the latest figures from Q3 2025, Axsome Therapeutics' Receivables is $215.8 million, which was up 5596.52% from $218.6 million recorded in Q2 2025.
- Axsome Therapeutics' 5-year Receivables high stood at $218.6 million for Q2 2025, and its period low was $16.2 million during Q2 2022.
- Over the past 4 years, Axsome Therapeutics' median Receivables value was $111.2 million (recorded in 2023), while the average stood at $112.4 million.
- As far as peak fluctuations go, Axsome Therapeutics' Receivables soared by 41375.17% in 2023, and later skyrocketed by 4489.84% in 2024.
- Quarter analysis of 4 years shows Axsome Therapeutics' Receivables stood at $46.8 million in 2022, then soared by 129.34% to $107.3 million in 2023, then surged by 44.9% to $155.5 million in 2024, then soared by 38.8% to $215.8 million in 2025.
- Its last three reported values are $215.8 million in Q3 2025, $218.6 million for Q2 2025, and $176.2 million during Q1 2025.